<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 304 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page303.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=304">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 304 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 304</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=304"><img src="../thumb/304.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Anti-Microbials - 18.12                                                        2020-04 / 267
       Side effects: Bld.dyscras., hyperlactat., lact. acidos. in absence of   concom.didanosine not recomm., co-infect.HIV pts.receiv.highly ac-  DIDIVIR, Cipla-Medpro [P/S]
       hypoxaem.& sev. hepatomegaly with steatos.somet.fatal., lipodys-  tive Anti-Retroviral ther.at incr.risk of ser.adverse effects, co-infect.  Emtricitabine 200 mg, tenofovir disoproxil fumarate 300 mg
       troph., headache, CNS effs.incl.  HIV pts.with advanc.cirrhos.receiv.highly active Anti-Retroviral ther.  Indications: In combinat.with other antiretrovir.in adults with
       periph. neuropathy/paraesthes, cough, nas. sympts., GI disturbs.,   at incr.risk of hepat.decompensat.& poss.death if treat.in combinat.  HIV-1 infect.
       pancreatit, liv.enzym./ser. amylase incr., skin reacts., arthralg, rhab-  with peginterferon alfa-2a, in the event of adverse reacts./lab. ab-  (S4) TABS, 44/20.2.8/0446
       domyolys., musculoskelet.pain, malaise, fatig., fev., anaem.poss.  norm. develop.modify dos.until advers.reacts. abate. pos.discont,if   715091-001: 30, R477,04
       req.bld.transfus., anorex., anx., depress., insomn., somnol., dizzin.,   intol.persists aft.dos.adjustm.  Dosage: 1 tab.once dly.without regard to food.
       convuls., loss of ment.acuity, cardiomyop., dyspn., skin & oral mu-  Warning: Do not use alone, monother.not eff.for chron. hepatit.C.  Contraindications: Safety & effic.not est.in hepatit. B vir.& HIV
       cosa pigmentat, liv.disords., sweat., myalg., myopathy, urin.freq.,   Drug interactions: In-vitro phosphorylat.of zidovudine & stavudine   co-infects., mod.to sev. uncontrol. kidn.fail., pregn.& lactat., safety
       gynaecomast., gen.pain, asthen.  inhibit., antiretrovir.eff.of didanosine potent.& expos.to didanosine   & effic. in paed.pts.not est., concom.drugs contain lamivudine.
       Warnings and special precautions: Pts.with risk fact.for liv.dis.,   or its act.metabolit.incr. in vitro.  Side effects: Lactic.acidos.& sev.hepatomegaly with steatos.incl.
       discont.in pts.develop. lab. findings suggest.lact.acidos./hepatotox.,   fatal., sev.ac.exacerbat.of hepatit. B aft.discontinuat., ac.ren.fail.&
       mitochondr. dysfunct., consid.pancreatit.if pt. devel. abdom.pain/  CYCLIVEX, (Aspen Pharmacare: Pharma) Pharmacare [P/S]  Fanconi syndr., anaem., neutropen., hyperglycaem., hypertriglyceri-
                                     Acyclovir.
       naus./vomit./elev. biochemic. markers & discont.until diagnos.of   daem., headache, asthen., depress. disord., dizzin., sleep disturbs.,
       pancreatit. excl., ren./hepat.impairm., safety & effic.not est.in pts.   Indications: Init.& recurr.H.simplex.infects.of skin & mucous mem-  neuropathy, periph. neurit., paraesthes., incr.cough, rhinit., GI dis-
                                     br., init.& recurr.genit.H.simplex., suppress. of recurr.genit.H.simplex
       with signific.underlying liv.disords./dis., monit. liv.funct.in pts.with   turbs., rais. liv.enzymes, hyperbilirubinaem., rash, hyperpigmentat.
       pre-exist.liv.dysfunct., also consult prod.lit.of concom.antiviral ther.  in immuno-competent.pts., prophylax.of H. simplex.infects.in im-  of palms &/soles, arthralg., myalg., allerg.reacts., hypophospha-
                                     munocompromis.pts., treatm.of H.zoster. infects. if lesions not
       for hepatit. B/C, monit. hepat.funct.for sev.mnths.aft.discont.in pts.   taem., insomn., anx., abdom./back/chest pain, pneumon., dyspn.,
       co-infect.with hepatit.B, pts.with chron. hepatit. B/C treat.with   older than 72 hrs., treatm.of Varicella-Zoster within 24 hrs.of typi-  pancreatit., hepatit., fev., sweat., weight loss, BMD decr., body fat
       antiretrovir.ther.are at incr. risk for sev.& potent.fatal hepat.adverse   cal chickenpox rash.  redistribut./accumulat., inflamm. respons.to indolent/resid.infects.
                                     (S4) TABS. 28/20.2.8/0715, 31/20.2.8/0298
       reacts., eval. for signs of fat redistribut., elderly, CV risk assessm.   necessit. furth.eval.& treatm.
       in pts.with evid.of lipodystrophy, immune reconstit. inflammat.syn-  824313-003: 200 mg, 25, R81,59  Special precautions: Monit.hepat.funct.for sev. mnths.if dis-
                                     860581-004: 400 mg, 70, R329,03
       dr., pts.to seek med. advice if experienc.joint pain/aches/stiffn./   cont.& pts.co-infect.with HIV & HBV, not recomm.as part of triple
       movem. diffic.as osteonecros.poss., opportunist. infects & other HIV   Dosage: Init.& recurr.skin & mucous membr. H.simplex.in-  nucleoside regim., obesity & prolong.nucleoside use poss.risk fact.for
                                     fects: Adults: 200 mg 5x/dly.at approx.4 hrly.interv., omit night-time
       complicat.still poss., ther.not proven to prev.HIV transmiss.through   lact.acidos., hepat.dis.risk fact., discont.if find. suggest.lact.acidos./
       sex.cont./ bld. contam., monit.haematolog.paramet., in case of sev.  dos.x5 days. Treatm.per.may be extend.if neccess.  hepatotoxic., test for hepatit.B bef.init.ther., imp.ren.funct., concom./
                                     In sev.immunocompromis.pts./pts.with imp. gut absorpt: dos.
       anaem./myelosuppress./pre-exist.bone marrow compromise where   may be doubl.to 400 mg or alternat. IV ther.  rec. nephrotox. meds., concom.didanosine & discont.if advers. effs.
       dos.adjustm.may be reqd./where discont.of one of the act.necess.  Suppress.of recur.genit.H.simplex infects.in immune-com-  develop, recom.concom.atazanavir be admin. with ritonavir, monit.
       use separ. preps., sero-convers to HIV+ status may still occ. despite   petent adults: 200 mg 4xdly, 6 hrly/ 400 mg 2xdly 12 hrly. Titrat.  BMD in pts.with patholog. bone fract.hist./at risk of osteopen., Ca
       prompt use & recommend.prophylact. dose must be strictly adher.  down to 200 mg 8-12 hrly. may prove effect. Interrupt at 6-12 mnthly.   & vit.D supplementat.poss benefic., elderly.
       to, monit.pts.receiv. concom.co-trimoxazole, avoid concom.high co-  interv.to observe any poss.changes.  Drug interactions: Conc.incr.with concom.drugs elimin.by act.
       trimoxazole dos.in Pneumocystis carinii pneumon./ toxoplasmos.,   H.simplex prophylax in immunocomprom. adults: 200 mg   tubul.secret., ser.conc.incr.by agents decr.ren.funct., Cmax & AUC of
       concom.phenytoin, monit.ren.funct./ haemotolog. paramet.with   4xdly 6 hrly.  didanosine incr., AUC & C min of atazanavir decr.
       concom.potent. nephrotox./myelo-suppress.agents, concom. pro-  In sev.compromis.pts./pts.with imp.gut absorpt: dos.may be   DIVUWIN, (Sanofi Aventis) Winthrop [P/S]
       phylact. antimicrob.ther., concom.self-admin. med.  doubl.to 400 mg.or IV therapy consid., durat.of therapy determin.  Lamivudine 150 mg, zidovudine 300 mg.
       Interactions: Poss.interacts.with meds. elimin.by act.ren.secret.,   by period at risk.  Indications: Treatm.of HIV- infect.as part of antiretrovir.combinat.
       co-trimoxazole incr.plasma lev., rifampicin decr. AUC, lamuvidine   H.zoster & Varicella-zoster infects.in adults: 800 mg 5xdly at   ther. in adults & childr.&gt; 12 yrs with progress. immunodefic., post
       poss.inhib. zalcitabine intracell.phosphorylat., alt.bld.lev.with phe-  approx. 4 hrly interv., omit night-time dos.x7 days.  expos. prophylax. in adults follow.occupat.expos.
       nytoin, probenecid incr.mean half-life & AUC of zidovudine., stavu-  Varicella-zoster infects.in adolescents (12-18 yrs): 800 mg   (S4) TABS, 46/20.2.8/0680
       dine intracell. phosphorylat.poss. inhib.by zidovudine, incr.incid.of   4xdly x5 days.  718081-001: 60, R486,45
       neutropen.with paracet., cert.agents incl.aspir./codeine/morph./   Contra-indications: Safety in pregn.not est., lactat.  Dosage: As a fix.dos.combinat.do not prescrib. when dos.adjustm.
       methadone/ indomethac./ketoprof./lorazepam/ oxazepam/ naprox./  Side-effects: Skin rash, headache, GI disturbs., immune suppress.  necess., Consult respect.PI’s for separ.agents dur. combin.ther.
       cimetidine/clofibrate/dapsone poss. alt. zidovudine metabol.by inhib.   pts.prone to acyclovir resist. mucocutan.H.simplex infects., resist-  Adults & childr.over 12yrs: 1 tab. 2xdly.
       glucoronidat. /direct.inhibit.hepat.microsom. metabol.  ance report. with varicella zoster virus.  Post expos.prophylax: Init.ther. pref.with.1-2 hrs aft. expos. Cont.
       COPEGUS, Roche [P/S]          Special precautions: Ren.impairm., pass.in breast milk., concom.  unt.confirm.of HIV status of source. Prophylact.course to be contin.
       Ribavirin                     nephrotox.meds.incr.risk of ren.impairm.  for 4 wks should source be confirm.as HIV pos. Dos: 1 tab 2x dly.for
       Indications: In combinat.with peginterferon alfa-2a/interferon al-  Drug interactions: Probenecid blocks acyclovir ren.clear.  4 wks. Dos.to be strict.adher.to. Discont. ther.as soon as source is
       fa-2a for chron.hepatit. C in adults posit.for ser.HCV RNA incl.those   CYMEVENE, Roche [P/S]  confirm.not to be HIV infect.
       with compensat. cirrhos.      Ganciclovir Na equiv.to ganciclovir  Contraindications: Abnorm.low neutrophil counts /haemoglobin
       (S4) TABS, 38/20.2.8/0181     Indications: Prev.& treatm.of life-threaten./sight-threaten.cyto-  lev., concom.stavudine/ ribavirin & zalcitabine, safety in pregn.&
       704195-001: 200 mg, 42, R391,62  megalovirus dis.in immuno-comprom. pts., prevent.of CMV dis.in   lactat.not est., safety & effic.in childr.und.12 yrs.not est., concom.
       Dosage: Admin by experienced physic. Use as combin. ther. Mono-  transplant recipients.  IV ganciclovir/foscarnet not recomm., concom.meds.assoc.with
       ther.not effect. Caut.when handl. brok. tabs.& avoid direct contact   (S4) INJ, [P/S] Y/20.2.8/291. 500 mg.  develop.of pancreatit.
       with skin/ muc.membr. Admin in 2 div.dos.with food.   793175-011: 5x10 ml vials, R4 100,21  Side-effects: Bld.dyscras., pancreatit ., hyperlactataem., lact.aci-
       See lit.for dos.regimens & modificat. guidelines in pres.of CV dis.  Dosage: Admin.inj.only by IV infus. Indiv.treatm. Change of dos.to   dos., body fat redistribut./ accumulat, hypertriglyceridaem., hyper-
       Contraindications: Pregn./ intent.of pregn., men whose female   be based on reg.clinic.& haemtologic. assessm.  cholesterolaem., insul.resist., hyperglycaem., paraesthes., periph.
       partn.is pregn., haemoglobinopathies, auto-immune hepatit., mod   CMV retinitis: Induct.treatm: 5 mg/kg infus.IV at constant rate   neuropathy, headache, cough, nas.sympts., anaphylax., GI disords.,
       to sev hepat.Child-Pugh class B&C, mod.to sev.ren. impairm., chil-  over 1 hr every 12 hrs. x14-21 days in pts.with norm.ren.funct. Maint.   elev.ser. amylase, tran.rise in AST/ALT, rais.bilirub.lev., pancreatit.,
       dr.& adolesc.und.18 yrs.      treatm: 5 mg /kg as IV infus.over 1 hr.once dly.x7 days/wk OR 6 mg/  lact.acidos.& sev.hepatomegaly with steatos., hepatit.B post-treatm.
       Side effects: Teratogen., haemolyt.anaem.within 1-2 wks of   kg once dly.x5 days./wk. Dis.progress. treatm: Indefin.treatm.may   exacerbat., hepatotox., skin rash, alopec., nail/skin pigmentat., urti-
       treatm., worsen.card.dis., MI, hypersens. reacts., incr.uric acid due   be reqd.in AIDS pts. Progress.of retinit.may occur in which case in-  car., prurit., arthralg., musc.disords.incl. musculoskelet.pain, rhabdo-
                                                                  myolys., malaise, fatig., fev., psych.disords., CNS disords.incl.loss of
       to haemolys., U& LRTI, UTI, skin infect., endocardit., otit.externa,   duct. treatm.should be giv.again.
       malign. hepat.neoplasm, anaem., thrombocytopen., lymphadenop-  Transplant recipient prophylax: Induct.treatm: 5 mg/kg infus.  ment. acuity & convuls., cardiomyopathy, dyspn., cough, urin.freq.,
                                                                  gynaecomast., gen.pain, chills, influenza-like syndr., taste pervers.,
       athy, pancytoen, aplast.anaem., sarcoidos., thyroidit., anaphylax.,   IV over 1 hr every 12 hrs. x7-14 days in pts.with norm. ren.funct.
       SLE, rheumatoid arthrit., idiopath./thrombot. thrombocytopen. pur-  Maint.treatm: 5 mg /kg as IV infus. over 1 hr.once dly.x7 days/wk   immune reconstit. syndr.
                                                                  Warnings and special precautions: Not proven to prev. HIV
       pura, hypo-/hyperthyroid., diab., dehydrat., psych. disords.incl.suid.  OR 6 mg/kg once dly.x5 days/wk.
       ideat..& suicide, headache, dizzin., imp.conc./memory, syncope,   Contraindications: Pregn., lactat., acylovir hypersens., eval.treatm.  transmiss., opportunist.infects & other HIV complicat.still poss.,
                                                                  monit.haematolog. paramet., zidov.dos.adjustm.poss.req if sev.
       weakn., migraine, hypo-/hyperaesthes., paraesthes., trem., taste   initiat.if absolute neutrophil count bel.500 cells/microlitre, congenit.
       disturbs., hear.loss, periph.neuropathy, coma, convuls., fac.palsy,   / neonatal CMV infects., neutropen., thrombocytopen., pancytopen.,   anaem./ myelosuppres.occurs/in pts.with pre-exist. comprom.bone
                                                                  marrow, discont.use if pancreat. suspect., ren./hepat.funct.impairm.,
       blurr.vis., eye pain & inflammat., xerophthalm., retin.haemorrh./-  myelosuppress. meds., do not mix.with other IV prod.  pts. with known risk facts.for liv.dis., discont.in pts. develop. lab.
       vasc. disord./ -detachm., optic neuropathy, papilloed., corn. ulc.,   Side effects: Thrombocytopen., pancytopen., CNS effs., GI dis-
       vis.loss, vertigo, earache, tachycard., palpitat., periph.oed., CHF,   turbs., asthen., pain & infect., anaem., fev., rash, loc.reacts.at inj.  findings suggest.lact.acidos./ hepatotox., monit.pts.receiv.concom.
                                                                  co-trimoxazole, monit.liv.funct.in pts.with pre-exist. liv.dysfunct., pts.
       angina, supraventric. tachycard., dysrhythm., atrial fibrillat., peri-  site., photosens., hypersens., hepatit., jaund., malaise, sepsis, oed.,
       cardit., flush., hypertens., cerebr.haemorrh., dyspn., cough, exert.   chills., CV effs., vis.disturbs.incl.retin.detachm., deafn., hypochrom.  esp.obese women with hepatomegaly/hepatit./other risk fact.for
                                                                  liv.dis./ hepat.steatos., safety & effic.not est.in hepatit.B co-infect.,
       dyspn., epistax., nasopharyngit., sinus & nas. congest., rhinit., sore   anaem., splenomeg., eosinophil., marr.depress., dissemin.intravasc.
       throat, wheez., interstit. pneumonit.with fatal outcome, pulm.em-  coagulopathy, metabol./nutrit.disords., arthralg., myalg., leg cramps.,   adv.cirrhot.liv.dis.due to chron.hepatit.B infect., not proven to prev.
                                                                  HIV transmiss., monit. hepat.funct.for sev.mnths.aft.discont.in pts.
       bol., GI disturbs., dysphag., GI bleed., pept.ulc., pancreatit., hepat.  musc.twitch., bronchosp., cough, dyspn., resp.fail., prurit., urticar.,
       dysfunct.& fail., alopec., prurit., dry skin, rash, incr.sweat., psorias.,   alopec., acne, breast pain, UTI, urin.freq., albuminur., haematur.,   co-infect.with hepatit.B, discont.if hyperlactatem.& metabol./lact.
                                                                  acidos. /progress.hepatomeg./rapid. elev. aminotransferas.lev.de-
       urticar., eczema, photosens., tox.epiderm.necrolys., Stev. Johns.   abnorm.kidn.funct., kidn.fail., impot.  velop., eval.for signs of fat redistribut., meas.fast ser.& bld.gluc.,
       syndr., angioed, erythema multiforme, myalg., arthralg., back pain,   Special precautions: Due to the myelosuppres. nature WBC   manage lipid disords as clinic.appropr., pts.to seek med. advice if
       arthrit, musc.weakn., bone/ neck & musculoskelet.pain, musc.  counts recomm.every 2 days dur.1st 14 days of treatm., dos.reduct.  experienc.joint pain/aches/stiffn./ movem.diffic.as osteonecros.
       cramps, myosit., impot., pyrex., rigors, pain, asthen., inj.site react.,   to be consid.in leucopen. /sev.neutropen./anaemia & thrombocy-  poss., cons.benef./ risk dur.pregn., elderly
       irritabil., chest pain, flu-like illn., malaise, lethargy, hot flush, thirst,   topen., full bld.& platelet counts wkly, limit. clinic.exper.in childr.  Drug interactions: Poss.interacts.with meds. elimin.by act.ren.
       weight decr., subst.OD,       hence caref.consid. necess., elderly, women of child bear.potent.&   secret., trimethoprim incr. lamivudine plasma lev., intracell.phos-
       Special precautions: Ref.to peginterferon/ interferon alfa-2a   men to use effect.contracept.for up to 90 days due to teratogenic.  phorylat.of concom. zalcitabine poss.inibit., zidovudine metabol.
       lit., obtain negat.pregn.test immed. prior to init.ther., discont.im-  observ.in animals, imp.ren.funct., adeq. hydrat, monit.for didano-  poss.alt.by meds.direct.inhibit.hepat. microsom. metabol./com-
       med.if ac. hypersens. develop.& instit.appropr.treatm., signific. /  sine toxic., avoid concom. imipenem-cilastatin as seiz.report., con-  petit.glucuronidat. inhibit., phenytoin bld.lev.alt., poss.incr.toxic.
       unstable card.dis.hist., 2 forms of adeq. contracept.dur.& for at   sid. ganciclov.a potent.carcinogen., toxic.incr.by rapid bolus/IV inj.  risk with potent nephrotox./myelosuppress.meds., probenecid
       least 6 mnths.aft.treatm. complet., assoc.anaem. poss.results in   Drug interactions: Meds.which inhib.replicat.of rapidly-divid.  incr.zidovudine mean half-life & area und. plasma conc.curve., ri-
       deteriorat. card funct./exacerbat.of coron.dis.sympt., monit. pre-  cell populat.might have combin.addit. toxic effs., zidovudine’s AUC   fampicin decr. zidovudine AUC, ribavirin/stavudine is antagonist.
       dispos.pts.for gout, discont.treatm.if hepat. decompens.develops,   may incr.& ganciclovir’s AUC may decr.when given concom., con-
       do not init.in creatin. clear.&lt;50 ml/min/if ren.impairm. occurs.dur.   com. mycophenolate incr.conc.of both meds., addit. toxic.poss.  in vitro, incr.incid.of neutropen.with paracet., low. AUC/ C maxT max
                                                                  with clarithromycin.
       treatm., obtain std.haematolog.tests & bld.chem. pre- treatm./at   with pentamidine/trimethoprim/ sulpha combinat. /fluocytosine/
       wks.2-4 of treatm.& as clinic. indicat., monit.plasma HIV RNA lev.  dapsone/vincrist./ vinblastine/ adriamycin/amphotericin B & other   DOZRA, Novagen [P/S]
       with concom. zidovudine & stavudine & review treatm.if lev.incr.,   cytotox. agents.  Zidovudine</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page303.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page299.html">299</a>&nbsp;&nbsp;&nbsp;<a href="page300.html">300</a>&nbsp;&nbsp;&nbsp;<a href="page301.html">301</a>&nbsp;&nbsp;&nbsp;<a href="page302.html">302</a>&nbsp;&nbsp;&nbsp;<a href="page303.html">303</a>&nbsp;&nbsp;&nbsp;<a href="page304.html">304</a>&nbsp;&nbsp;&nbsp;<a href="page305.html">305</a>&nbsp;&nbsp;&nbsp;<a href="page306.html">306</a>&nbsp;&nbsp;&nbsp;<a href="page307.html">307</a>&nbsp;&nbsp;&nbsp;<a href="page308.html">308</a>&nbsp;&nbsp;&nbsp;<a href="page309.html">309</a>
             </td>
             <td width="35%"><a href="page305.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page305.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
